Category Archive: Publications

Feb 17

New Book – Principles of Anticancer Drug Development

Recently, Humana Press/Springer published a new book, Principles of Anticancer Drug Development. Neil Clendeninn M.D., Ph.D., a Senior Clinical Research Physician for Cato Research, served as an editor for the book, which has been described as a practical guide to the design, conduction, analysis and reporting of clinical trials with anticancer drugs.

Dec 07

Biotech Financing: Those That Adapt to Change Will Survive

In the October issue of Biotechnology Focus, Cato Research’s very own Chief Financial Officer and Principal of Cato BioVentures, Daniel Pharand, discusses the recent shift and latest trends in financing within the biotechnology industry.  “There have been a number of trends in the biotech funding world since its last bubble and bust in the early …

Continue reading »

Aug 20

Important Steps Forward for Early Detection and Diagnose of Alzheimer’s Disease

Image via Wikipedia In a recent report by Geert De Meyer of Ghent University in Belgium and colleagues, titled “Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People” (Arch Neurol. 2010;67(8):949-956) it was demonstrated that measuring certain proteins in spinal fluid can accurately diagnose Alzheimer’s and predict which patients with memory problems will develop …

Continue reading »

May 14

Advice from the FDA, Part 2: Making Your eCTD Submission Reviewer-Friendly

Cato’s Director of Regulatory Operations, Evan Richardson, authored a guest blog post featured on PharmPro.com today.  PharmPro.com is the website for Pharmaceutical Processing magazine, offering a wealth of  information on products, technologies and applications for pharmaceutical and biopharmaceutical professionals. Evan’s post, “Advice from the FDA, Part 2: Making Your eCTD Submission Reviewer-Friendly,” offers practical advice …

Continue reading »

May 12

Approval of Therapeutic Cancer Vaccines

Last month, Dendreon was granted approval for Provenge®, the first cell based cancer vaccine for treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.  Provenge is the first cancer treatment that utilizes the strength of the patient’s own immune system to fight tumors.  This approval could mark the beginning of a …

Continue reading »

Apr 08

Advice from the FDA, Part 1: Technical Errors to Avoid in Your eCTD Submissions

Cato’s Director of Regulatory Operations, Evan Richardson, authored a guest blog post featured on PharmPro.com today.  PharmPro.com is the website for Pharmaceutical Processing magazine, offering a wealth of  information on products, technologies and applications for pharmaceutical and biopharmaceutical professionals. Evan’s post, “Advice from the FDA, Part 1: Technical Errors to Avoid in Your eCTD Submissions,” …

Continue reading »

Feb 11

GxP Lifeline features article by Cato’s Rachel Cooper

The February 2010 issue of the GxP Lifeline – Pharmaceutical newsletter made it’s debut today, and Cato Research Project Manager Rachel Cooper is highlighted as one of the featured authors. Rachel’s article, titled “From the Project Manager’s Toolbox: Strategies for eCTD Marketing Application Submissions,” provides a wealth of information for a project manager taking on …

Continue reading »

Feb 11

GxP Lifeline features article by Cato's Rachel Cooper

The February 2010 issue of the GxP Lifeline – Pharmaceutical newsletter made it’s debut today, and Cato Research Project Manager Rachel Cooper is highlighted as one of the featured authors. Rachel’s article, titled “From the Project Manager’s Toolbox: Strategies for eCTD Marketing Application Submissions,” provides a wealth of information for a project manager taking on …

Continue reading »